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ABSTRACT
Background Deletions in the Xq22.3–Xq23 region,
inclusive of COL4A5, have been associated with a
contiguous gene deletion syndrome characterised by
Alport syndrome with intellectual disability (Mental
retardation), Midface hypoplasia and Elliptocytosis
(AMME). The extrarenal biological and clinical
signiﬁcance of neighbouring genes to the Alport locus
has been largely speculative. We sought to discover a
genetic cause for two half-brothers presenting with
nephrocalcinosis, early speech and language delay and
midface hypoplasia with submucous cleft palate and
biﬁd uvula.
Methods Whole exome sequencing was undertaken on
maternal half-siblings. In-house genomic analysis
included extraction of all shared variants on the X
chromosome in keeping with X-linked inheritance.
Patient-speciﬁc mutants were transfected into three cell
lines and microscopically visualised to assess the nuclear
expression pattern of the mutant protein.
Results In the affected half-brothers, we identiﬁed a
hemizygous novel non-synonymous variant of unknown
signiﬁcance in AMMECR1 (c.G530A; p.G177D), a gene
residing in the AMME disease locus. Transfected cell
lines with the p.G177D mutation showed aberrant
nuclear localisation patterns when compared with the
wild type. Blood ﬁlms revealed the presence of
elliptocytes in the older brother.
Conclusions Our study shows that a single missense
mutation in AMMECR1 causes a phenotype of midface
hypoplasia, mild intellectual disability and the presence
of elliptocytes, previously reported as part of a
contiguous gene deletion syndrome. Functional analysis
conﬁrms mutant-speciﬁc protein dysfunction. We
conclude that AMMECR1 is a critical gene in the
pathogenesis of AMME, causing midface hypoplasia and
elliptocytosis and contributing to early speech and
language delay, infantile hypotonia and hearing loss,
and may play a role in dysmorphism, nephrocalcinosis
and submucous cleft palate.
INTRODUCTION
The chromosomal region Xq22.3–Xq23 encom-
passes the entire COL4A5 gene and its adjacent
genes extending towards the telomere: GUCY2F,
NXT2, KCNE1L, ACSL4, TMEM164, MIR3978,
AMMECR1, SNORD96B, RGAG1, TDGF3,
CHRDL1, PAK3 and DCX. Deletions in this region
have been associated with a contiguous gene dele-
tion syndrome characterised by Alport syndrome
with intellectual disability, midface hypoplasia and
elliptocytosis (AMME (MIM: 300194)). The ﬁrst
report of AMME was by Jonsson et al1 who
reported a microdeletion spanning from COL4A6
(upstream of COL4A5) to TDGF3 in two affected
brothers. COL4A5, the gene underlying X-linked
Alport syndrome (AS (MIM: 301050)), maps to
Xq22.3 and is well known to cause renal failure,
sensorineural hearing loss and ocular abnormal-
ities.2 However, mutations in COL4A5 do not
account for the additional manifestations seen in
AMME; this suggests that neighbouring genes of
the Alport locus contribute to the rest of the
phenotype. Until recently, the signiﬁcance of these
adjacent genes has been largely speculative.
We report on two maternal half-brothers, pre-
senting with nephrocalcinosis and midface hypopla-
sia. The older sibling also has deafness and
elliptocytosis. By application of next-generation
sequencing, we identiﬁed a novel point mutation in
AMMECR1 (c.G530A; p.G177D) present in the
half-siblings and carried in the mother. We show
that this variant alone causes midface hypoplasia,
speech and language delay and elliptocytosis,
emphasising the critical importance of AMMECR1
in the pathogenesis of AMME.
METHODS
Two maternal Caucasian half-siblings presenting
with overlapping phenotypes (ﬁgure 1) were ascer-
tained through the paediatric nephrology service at
University Hospital Southampton.
Proband II(1)
Following a pregnancy complicated by extreme
hyperemesis, proband II(1) was delivered by elect-
ive caesarean section for breech presentation weigh-
ing 3.59 kg ( just above 50th centile). Antenatal
screening showed evidence of fetal nuchal oedema,
bilateral talipes, short femurs and decreased liquor.
An amniocentesis showed a normal 46,XY karyo-
type. Shortly after birth, proband II(1) was noted
to have hypotonia and poor feeding. Methylation
testing of SNRPN exon 1 in the PWS/AS critical
region was normal. Apparently short femora, bilat-
eral talipes, widely spaced nipples, a ﬂat facial
proﬁle with a ﬂat nasal bridge, downslanting palpe-
bral ﬁssures, thin upper lip, micrognathia, short
neck, folded upper helix to the ears, ﬁfth ﬁnger
clinodactyly and additional right nipple were
noted. He had surgical correction for a submucous
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cleft palate and biﬁd uvula. An abdominal ultrasound scan
showed possible nephrocalcinosis. An ultrasound of the head
was normal.
Aged 2 months, he underwent bilateral percutaneous achilles
tenotomies. His length was just above the 0.4th centile, weight
on the 2nd centile and with a disproportionately large head cir-
cumference on the 50th centile. Bilateral nephrocalcinosis was
conﬁrmed on a repeat ultrasound scan. At seven and a half
months, following application of the Alberta Infant Motor
Scale,3 he was assessed to have mild-to-moderate delay in motor
and communication skills. Diagnoses of Stickler syndrome and
chondrodysplasia punctata were considered. Very long chain
fatty acid tests were normal. Vision and fundal examination
were normal on formal ophthalmic examination. Skeletal
surveys performed just before his ﬁrst birthday, and repeated
when aged 4, reported no skeletal abnormality and speciﬁcally
no epiphysial stippling. He was discharged from physiotherapy,
occupational therapy and speech and language therapy before
his second birthday, having made improvements in his gross
motor development and feeding following cleft palate repair.
Aged 23 months, he had a normal brain MRI with no evidence
of hypothalamic or pituitary abnormality, ruling out a midline
defect. He did not get his ﬁrst teeth until he was 21 months old.
Aged 3, his short stature (0.4th centile) was calculated to be
within the target centile range for his parents’ heights. His head
remained disproportionately large (50th centile) with weight on
the 2nd centile. Aged 4, he was noted to have mild facial dys-
morphology consisting of a ﬂat midface with a large, broad fore-
head and small mouth with crowded teeth. There were bulbous
tips to his toes and marked lumbar lordosis without scoliosis.
There was a normal sitting height to leg length ratio. He had
started mainstream school; however, there was still parental
concern regarding slow progress and poor concentration. He
had repeatedly elevated urine calcium:creatinine ratios, but a
persistently normal plasma calcium concentration. Further ultra-
sound scans corroborated previous ﬁndings of nephrocalcinosis.
At his most recent review, aged 11, proband II(1) remained in
mainstream school. His facial dysmorphic features were much
less apparent than observed previously, and his growth para-
meters were unchanged. He had bilateral mixed hearing loss
requiring hearing aids; sensorineural hearing loss was ﬁrst
detected at age 3, despite a normal audiogram 1 year previously.
His bone conduction threshold was 35–45 dB bilaterally,
whereas air conduction showed a threshold of 45–50 dB bilat-
erally. He had also begun to suffer from migraines. He had mild
joint hypermobility but much improved hypotonia. He had per-
sistent nephrocalcinosis with intermittent hypercalciuria.
Younger maternal half-brother II(2)
Proband II(2) was born by emergency caesarean section for
failure to progress at 39 weeks’ gestation weighing 3.40 kg. His
pregnancy was complicated by polyhydramnios and hyperemesis
Figure 1 (A) Family pedigree for
proband II(1), and maternal
half-brother II(2) with genotype
information for all individuals tested.
Affected individuals are in black. The
maternal parents were phenotypically
normal. Asterisk deﬁnes individuals
who underwent whole exome
sequencing. (B) Photographs of
proband II(1) (taken at 11 months)
(left) and proband II(2) (taken at
2 years and 5 months) (right).
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similar to his older half-brother. Otherwise, antenatal screening
was normal. He had congenital dysplasia of the hips treated
with a Pavlik harness. Retrospective review of early radiographs
showed no evidence of epiphysial stippling. Shortly after birth,
it was noted that he shared dysmorphic facial features with his
half-brother. He also had a submucous cleft palate, biﬁd uvula
and short stature. Aged 1, he underwent a renal ultrasound
scan, which revealed bilateral renal dysplasia. The right kidney
measured 5.4 cm and the left was 6 cm. There was early nephro-
calcinosis. A simple cyst was seen in the midpole of the left
kidney. He did not have the signiﬁcant infantile hypotonia
observed in his brother and met his motor milestones appropri-
ately. However, he had more signiﬁcant speech and language
delay, with no words at 2 years of age. Aged 3, he had made
progress and was putting two words together. Similar to his
brother, his growth parameters followed below the 0.4th centile
for height, with weight between the 2nd and 9th centile and
head circumference between the 25th and 50th centiles. He had
joint hypermobility, right esotropia and viral-induced wheeze.
Aged 4, an audiogram showed air conduction thresholds of
20 dB bilaterally, just within the normal range. Bone conduction
was tested only on the right with a threshold of 10 dB across
the frequency range. This audiogram showed deterioration from
one previously. Aged 5, proband II(2) was developing well and
displayed a degree of developmental catch up with improved
speech and language skills; he attended a normal school. His
facial dysmorphology was also less apparent.
Mother I(2)
Their mother was of normal intelligence. Renal ultrasound scan
performed when she was 34 years was normal. She had normal
renal function and there was no evidence of hypercalciuria. The
maternal grandparents were deceased but were reported as
showing none of the abnormal phenotypic features of the pro-
bands. There were no other male relatives.
Clinical genetic testing
An array comparative genomic hybridisation (CGH) was per-
formed on proband II(1) and showed no copy number varia-
tions (CNVs; Agilent 44 K oligo array-CGH). A
multidisciplinary discussion informed selection of a gene
candidate, OCRL1, an X-linked gene involved in Lowe oculo-
cerebrorenal syndrome, Fanconi syndrome, intellectual disability
and nephrocalcinosis (MIM: 309000).4 Sanger sequencing of
OCRL1 revealed no mutations in either sibling. As a result, the
half-siblings were referred to the Southampton Genomic
Informatics Group for whole exome sequencing.
DNA extraction
Genomic DNA (gDNA) was extracted from peripheral venous
blood samples collected in an ethylenediaminetetraacetic acid
tube. DNA concentration was estimated using the Qubit 2.0
Fluorometer. The average gDNA yield obtained was 150 mg/
mL. Approximately, 20 mg of gDNA was used per patient for
next-generation sequencing.
Whole exome sequencing data generation and data analysis
Whole exome sequencing was performed on two maternal half-
siblings using the Agilent SureSelect Human all Exon 51 Mb V.5
capture kit. As previously described,5 6 FASTQ raw data gener-
ated from Illumina paired-end sequencing were aligned against
the human reference genome (hg19) using Novoalign (novoa-
lign/2.08.02). SAMtools mpileup tool (samtools/0.1.19)7 was
used to detect the variation from the mapping information to
call SNPs and short INDELs from the alignment ﬁle.
ANNOVAR (annovar/21 February 2013)8 was applied for
variant annotation against a database of RefSeq transcripts. A
bespoke script was used to assign individual variants as: ‘novel’
if they were not previously reported in the dbSNP137 data-
bases,9 1000 Genomes Project,10 the Exome Variant Server
(EVS) of European Americans of the NHLI-ESP project with
6500 exomes (http://evs.gs.washington.edu/EVS/),11 in 46 unre-
lated human subjects sequenced by Complete Genomics12 or in
the Southampton database of reference exomes. Resultant
variant ﬁles for each individual were subjected to further
in-house quality control tests to detect DNA sample contamin-
ation and ensure sex concordance by assessing autosomal and X
chromosome heterozygosity.13 Variant sharing between the two
siblings was assessed to conﬁrm sample relationships, and
VerifyBamID14 was used to check for sample contamination.
Sample provenance was conﬁrmed by independent genotyping
of a validated SNP panel, developed speciﬁcally for exome
data.15 CNVs across the Xq22.3–Xq23 region were assessed
using the R package ExomeDepth.16
Gene selection
Despite no mutations identiﬁed by Sanger sequencing, OCRL1
was reassessed using an alternative sequencing resource. The
segregation pattern in the family was strongly suggestive of
X-linked recessive inheritance; both maternal half-siblings were
affected despite a healthy mother, which suggested they were
hemizygous for the mutant allele. The genomic analysis was,
therefore, extended to extract all variations on the X chromo-
some common to the half-siblings. Additionally, we screened for
rare, damaging variants across Xq22.3–Xq23 as well as a panel
of known genes associated with idiopathic hypercalciuria/
nephrocalcinosis (see online supplementary methods).
Site-directed mutagenesis
PCMV6-AC-GFP-tagged AMMECR1 vector was obtained from
Origene (RG212378). Site-directed mutagenesis was carried out
to achieve the G>A point mutation within position 177 in exon
2 of variant 1 of AMMECR1 to confer substitution of amino
acid glycine with aspartate. Primers were designed containing
the G>A point mutation: forward primer: CGTGGATGCAT
AGATACTTTTTCTGCC; reverse primer: GGCAGAAAAAGT
ATCTATGCATCCACG. PCR mutagenesis was carried out using
Pfu Ultra DNA polymerase (Agilent Technologies, Stockport,
UK) and the following thermo cycle: 2 min at 95°C, (12×
cycles of 1 min at 95°C, 1 min at 55°C, 7.5 min at 68°C),
10 min at 68°C.17 DNA was digested with Dpn1 for 1 hour at
37°C to cleave the parental DNA template. The mutated vector
was sequenced to conﬁrm the AMMECR1 mutation (Source
BioScience).
Cell culture
HEK293, COS-7 and HeLa cells were plated on 22 mm sterile
coverslips in six-well plates in dulbecco modiﬁed eagle medium
(DMEM)/10% fetal calf serum (FCS). Cells in each well were
transiently transfected with 3 μg of either wild-type or mutant
GFP-tagged AMMECR1 using jetPEI transfection reagent,
according to the supplier’s instructions (Polyplus, Source
BioScience, Nottingham, UK). Cells transfected with jetPEI
reagent in the absence of DNA were used as a negative control.
DNA–PEI complexes were removed from cells after 4 hours and
replaced with fresh DMEM/10% FCS/1% Pen/strep.
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Microscopy
Twenty-four hours after transient transfection, cells were ﬁxed
with 4% (w/v) formaldehyde in phosphate buffered saline (PBS)
for 7 min at room temperature and mounted in VectaShield
mounting medium containing the nuclear stain, 4’,6-diamidino-
2-phenylindole (DAPI) (VectorLabs). Coverslips were mounted
and visualised using a ﬂuorescent microscope (Zeiss).
RESULTS
Quality control analysis
Exome data were high quality, evidenced by 80% mapped
coverage at a read depth of >20. For both samples, the average
depth of coverage was ≥60, online supplementary table 1. The
two samples from the affected siblings selected for exome ana-
lysis exhibited expected variant sharing for second-degree rela-
tives and no excess of sharing with any other sample on the
same despatch DNA plate. Autosomal and X-chromosome het-
erozygosity were consistent with gender. VerifyBamID14 did not
indicate any presence of contamination, and the application of a
SNP tracking panel15 conﬁrmed sample provenance.
Targeted gene analysis
No coding variation was found in OCRL1 consistent with
previous Sanger sequencing results. Therefore, the analysis
was extended to include all coding mutations across the X
chromosomes of the two brothers and three novel non-
synonymous mutations satisﬁed the ﬁltering criteria (as outlined
in table 1): AMMECR1 (c.G530A; p.G177D), KDM5C
(c.4082A; p.R1361K) and MAGEC1 (c.G919A; p.V307M). The
MAGEC1 (p.V307M) variant was poorly conserved (PhyloP18
score of 0.868789) and was not predicted to be damaging
and thus removed from downstream analysis. Although KDM5C
has been associated with Claes-Jensen Type Intellectual
Disability (MIM: 314690), which is a syndrome that has been
characterised by severe mental retardation, microcephaly and
large feet, we removed the novel variant (p.R1361K) from the
downstream analysis because it was not predicted to be dam-
aging by the in silico tools CADD19 and Polyphen220 (score of
1.2 and 0.033, respectively) Furthermore, KDM5C has been
associated with mental retardation, whereas we describe a mild
developmental delay inconsistent with the severity and nature of
the phenotype of Claes-Jensen. The novel non-synonymous
variant of unknown signiﬁcance in AMMECR1 (c.G530A; p.
G177D) warranted further scrutiny with high prediction scores
of pathogenicity (Phylop, Polyphen2, CADD and GERP++
scored this variant 0.998909, 1, 5.5 and 5.27, respectively).
Moreover, AMMECR1 has previously been deleted in patients
with Alport syndrome, mental retardation, midface hypoplasia
and elliptocytosis.1 21 22 No rare variants were identiﬁed in
known hypercalciuria genes (see online supplementary results
1), although CLDN14 and PTH had suboptimal gene coverage
by the Agilent V5 capture kit (45% and 86%, respectively). All
other hypercalciuria genes had >90% coverage.
Mutation within AMMECR1
The AMMECR1 mutation segregating in our family causes a
G>A change at genomic position 530, leading to a glycine to
aspartate change at codon 177 in exon 2. AMMECR1 encodes a
protein with a nuclear location whose function is still unknown.
The C-terminal region of AMMECR1 (from amino acid residue
122 to 333) is well conserved, and homologues appear in
species ranging from bacteria and archaea to eukaryotes. Exon 2
of AMMECR1 encodes a domain consisting of six amino acids
identically conserved throughout the course of evolution. The
putative nuclear localisation and the presence of a glycine-rich
N terminus raise the possibility that AMMECR1 has a regulatory
role.
No CNVs or rare variants were observed in either of the
affected brothers within the Xq22.3–Xq.23 region (average read
depth of 49.66). We conﬁrmed the AMMECR1 mutation using
traditional Sanger techniques and demonstrated hemizygous
status in the two half-brothers and heterozygous carrier status in
the unaffected mother. The probands’ maternal aunt did not
carry the AMMECR1 mutation.
Elliptocytosis
With evidence to support an association between AMMECR1
and elliptocytosis, blood ﬁlms were requested on the brothers at
ages 10 and 4, and both smears were reported blindly. The
younger brother, proband II(2), had a normal blood ﬁlm with
no evidence of elliptocytosis, but the older brother, proband II
(1), had an abnormal ﬁlm with scattered elliptocytes and aniso-
cytosis. A repeat blood ﬁlm on proband II(1) 10 months later
conﬁrmed the presence of elliptocytes, though the ﬁndings were
subtle.
Functional analysis
Analysis of AMMECR1 protein was assessed by GFP expression
in transfected cell lines. Colocalisation of GFP with the nuclear
DAPI stain was observed in both mutant and wild-type trans-
fected cells, showing localisation of AMMECR1 protein within
the nucleus (ﬁgure 2). The expression pattern of wild-type
AMMECR1 was spherical, overlaying the DAPI staining com-
pletely. Mutant AMMECR1 expression was distinct from wild
type in all three cell lines tested, with HEK293, COS-7 and
HeLa cells exhibiting non-uniform GFP expression within the
nucleus. The number of GFP-positive cells was also reduced fol-
lowing transfection with mutant AMMECR1 compared with
the wild type. These data conﬁrm that the G>A point mutation
Table 1 Three novel non-synonymous mutations that satisfied the filtering criteria across the 323 variants shared on the X chromosomes
between the two half-brothers
Chromosome
bp
position
(hg19) Gene
Variant
type Variant info Phylop+ Polyphen CADD Gerp++
X 109507771 AMMECR1 ns AMMECR1:NM_015365:exon2:c.G530A:p.G177D 0.998909 1 5.776826 5.27
X 53221984 KDM5C ns KDM5C:NM_001146702:exon24:c.G4082A:p.R1361K 0.033 1.26541
X 140994109 MAGEC1 ns MAGEC1:NM_005462:exon4:c.G919A:p.V307M 0.868789 0.512688 0.157
A total of 18 049 variants were shared between the half-siblings. The filtering strategy applied was limited to shared variants on the X chromosome only (323 annotated). 318 variants
were removed due to their occurrence within the Southampton control cohort of exomes (n=156) regardless of annotated zygosity. Of the five remaining variants, one was removed
due to its synonymous annotation, and another was disregarded due to its low MaxEnt splicing score (<3). Three novel (absent from ExAC server, dbSNP and the Southampton in-
house control database) non-synonymous variants satisfied the full filtering criteria. Ns, non-synonymous; sp, splicing.
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within position 177 of exon 2 of AMMECR1 affects the expres-
sion pattern of this protein within the nucleus.
DISCUSSION
We have identiﬁed a single base substitution (G>A) causing a
missense mutation in which a non-polar glycine amino acid
residue is replaced with a negatively charged aspartate in the
AMMECR1 protein. The observed variant codes for a highly
conserved residue of AMMECR1 within a highly conserved
six-amino-acid motif (LRGCIG). The variant appears novel to
this pedigree not occurring in our database of local exomes nor
in the publicly available variant repositories.
Functional analysis shows that the G>A point mutation
within amino acid 177 of the AMMECR1 protein affects
nuclear localisation. Proteasome complexes found within the
cytoplasm and nucleus are responsible for targeted degradation
of mal-folded or damaged proteins occurring due to missense or
non-sense mutations, as well as denaturation and biosynthetic
errors.23 24 The expression pattern of mutated AMMECR1 we
observed within the nucleus is consistent with the altered
protein being targeted for degradation by this system. The local-
isation pattern of the mutant AMMECR1-GFP protein has simi-
larity with the localisation of subunits of the 20S nuclear
proteasome, previously described by Baldin et al.25 The
mutated AMMECR1 protein may therefore be targeted for deg-
radation within the nucleus. Degradation of AMMECR1 is also
consistent with reduced GFP expression observed in cells trans-
fected with mutant AMMECR1 compared with wild type.
Disease states caused by proteolytic degradation of mal-folded
proteins as a result of missense mutations include cystic ﬁbrosis,
where targeted degradation of the mutant form of the cystic
ﬁbrosis transmembrane conductance regulator (CFTR) protein,
caused by a missense mutation, prevents normal functioning.24
Literature describing AMMECR1 is sparse; its description and
name (Alport syndrome, Mental retardation, Midface hypopla-
sia and Elliptocytosis Chromosomal Region gene 1) is derived
from its cytogenic location within Xq22.3–Xq23 and its previ-
ous association with a very rare contiguous gene deletion syn-
drome originally named Alport syndrome, mental retardation,
midface hypoplasia and elliptocytosis (AMME). Jonsson et al1
ﬁrst described AMME caused by a deletion including COL4A5
(Xq22.3) extending proximally to include AMMECR1.
We found a striking resemblance between proband II(1) har-
bouring a single point mutation in AMMECR1 and the patient
originally reported by Jonsson et al (ﬁgure 3). Contiguous gene
deletions of varying sizes within Xq22.3–Xq23 manifest in phe-
notypes that partially or completely overlap the AMME disease
spectrum have been described in ﬁve previous reports of which
three were inclusive of the AMMECR1 gene (ﬁgure 4). Most of
these deletions involve COL4A5, the major cause of Alport syn-
drome, yet mutations in COL4A5 do not account for the haem-
atological, dysmorphic and developmental characteristics
described in AMME. Therefore, it was surmised that these
extra-renal abnormalities were attributable to disruption of
genes adjacent to COL4A5, describing a new contiguous gene
deletion syndrome. Subsequently, there has been speculation
regarding the roles of genes in this region; however, for the
most part their biological signiﬁcance has been unresolved.
Although our report is based on a single family and we must be
tentative in drawing ﬁrm conclusions without further supportive
evidence, the variant is novel. That said, mutant-speciﬁc func-
tional evidence and the strong phenotypic overlap between the
dysmorphology observed in this study and the original AMME
case by Jonsson et al advance our understanding of the pheno-
typic/genotypic overlap between a single point mutation in
AMMECR1 and this contiguous gene deletion syndrome.
Although the single point mutation we observe has clear over-
lapping features of AMME with previously published cases, this
is in the absence of any Alport syndrome. The renal manifesta-
tions we describe are clinically disparate from Alport syndrome,
consistent with an absence of any COL4A5 mutations.
However, we are mindful that exome data cannot resolve (not
uncommon) deep intronic variants in COL4A5, and this is a
limitation of our study. As expected, haematuria is only
observed in Xq22.3–Xq23 regional deletions that overlap
COL4A5. Contrastingly, sensorineural hearing loss is consist-
ently observed across all case studies, regardless of direct
COL4A5 involvement. Proband II(1) in our study has hearing
Figure 2 G>A point mutation within position 177 of AMMECR1 gene alters the nuclear expression pattern of the protein. Representative images
of HEK293, COS-7 and HeLa cells 24 hours after transfection with a vector containing wild-type or mutant GFP-tagged AMMECR1. Nuclear
localisation of AMMECR1 was observed in both wild type and mutant; however, the non-uniform expression pattern of AMMECR1 was only found
in cells transfected with mutant AMMECR1.
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loss, as does the proband reported by Gazou et al26 who har-
boured a deletion not involving COL4A5 but inclusive of the
AMMECR1 gene. This may suggest that AMMECR1 is patho-
genically implicated in hearing loss, either alone, or as a modi-
ﬁer gene to COL4A5 due to their direct protein–protein
interaction (see online supplementary ﬁgure 1). The
sensorineural hearing loss in proband II(1) presented at age 3,
earlier than is typical in X-linked Alport syndrome and subse-
quently progressed. His half-brother, at aged 4, has air conduc-
tion values on the cusp of abnormality. His audiogram shows
deterioration from one previously, suggesting a progressive
pattern of hearing loss without congenital onset.
Intellectual disability is prevalent among individuals with
deletions across the Xq22.3-23 region; however, the degree is
varied. A critical region was identiﬁed by Meloni et al,27 who
identiﬁed four genes of interest (ACSL4, KCNE1L, NXT2 and
GUCY2F). ACSL4 has since been implicated in non-speciﬁc
X-linked mental retardation (MIM: 300387), favouring this
gene as the cause of intellectual disability in Xq22.3–Xq23
deletions.26 ACSL4 is deleted in all the microdeletion reports
(ﬁgure 4). Gazou et al have stated that “Deletion of ACSL4 is
probably the major, and possibly only, causative factor for intel-
lectual disability (ID)”…. The moderate degree of ID is similar
to patients with point mutations in ACSL4 and does therefore
not suggest additive effects by other genes. Absent or delayed
speech is the predominant phenotype in individuals reported by
Rodriguez et al,22 Robson et al28 and Jonsson et al1 but this
was of a greater severity than reported in these half-siblings
(table 2). Standardised, quantiﬁable measures would aid in
accurately mapping intellectual disability severity to chromo-
somal regions. We observed delayed speech, with no concerns
by the time the children attended school, although they did
have delayed reading and writing ability and there was parental
concern regarding slow progress and concentration difﬁculties.
Of course, delayed speech may be attributable to hearing
abnormalities or the submucous cleft palates. Both abnormalities
were corrected (with hearing aids and cleft palate repair), which
may explain the improvement in speech and language develop-
ment. Other reports1 22 26 28 include generalised hypotonia,
contributing to developmental delay. Proband II(1) had signiﬁ-
cant infantile hypotonia1 and delay in gross motor skills in
addition. This may be in part secondary to joint hypermobility,
which persisted through childhood. As AMMECR1 is asso-
ciated in the published literature with ACSL429 (see online
supplementary ﬁgure 1), we propose that this may explain the
speech and language delay and early motor delay observed.
Midface hypoplasia is present in all but one (Gazou et al)
case studies involving the AMME locus.26 While no other
reports include cleft palate, midface hypoplasia is often
observed in individuals with this congenital abnormality. The
midface hypoplasia may represent a minimal expression of this
phenotype. The dysmorphology reported is variable and
includes anteverted nares, downslanting palpebral ﬁssures, peri-
palpebral fullness, fetal pads, deep-set eyes, wide nasal bridge,
broad nasal tip, long philtrum, thin upper lip, downturned
mouth, widely spaced teeth, supernumery teeth, facial hypo-
tonia, second toe syndactyly and clinodactyly. Of note, as with
our study, there are reports that the facial dysmorphism lessens
in severity over time.21
Within the AMME locus, elliptocytosis only occurs in regions
inclusive of AMMECR1, although its penetrance is varied; ellip-
tocytes were observed only in the blood ﬁlms of the elder
brother at age 10 and not in the younger sibling at age 4.
Haematological abnormalities were also absent from the pro-
bands reported by Gazou et al26 and Hoischen et al30 (although
the Hoischen proband was female with a uniallelic deletion). It
is noteworthy, however, that the elliptocytosis is a mild pheno-
type (ﬁgure 5). Scattered elliptocytes were present and reported
on both blood ﬁlms; however, their subtlety may not warrant an
obvious elliptocytosis diagnosis; that said, we report a similar
Figure 3 Colour photographs of proband II(1) (left) taken at
11 months and 9 years compared with black and white photos (right)
of the patient described by Jonsson et al with features of X-linked
AMME, taken at 6 months and 12 years. The facial features shared
between our study and that of Jonsson et al are remarkably striking;
shared facial dysmorphology includes a hypoplastic and ﬂat midface,
short neck, thin upper lip and a small jaw.
Figure 4 A comparison of deletions across Xq22.3–23 (pink) that
have been associated with AMME in ﬁve separate reports, in addition
to the point mutation in AMMECR1 from this study (black).
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Table 2 A comparison of phenotypes reported in the literature involving deletions around the Alport locus (Xq22.3) and extending towards the telomere
Feature
Jonsson et al1
proband (1)
Jonsson et al1
proband (2)
Robson et al28
proband (1)
Robson et al28
proband (2)
Rodriquez
et al22
proband (1)
Rodriquez
et al22
proband (2)
Gazou et al26
proband (1) Hoischen proband (1) This study II(1)
This study
II(2)
Sex Male Male Male Male Male Male Male Female Male Male
Region involved COL4A6 to TDGF3 COL4A6 to TDGF3 COL4A5 to ACSL4 COL4A5 to ACSL4 COL4A5 to
ACSL4
COL4A5 to
ACSL4
GUCY2F to
RGAG1
COL4A6 to DCX AMMECR1 AMMECR1
Short stature 5th centile 5th centile − − 5th centile − − N/A 0.4th centile <0.4th
centile
Infantile
hypotonia
+ + + + − − − N/A + -
Hypermobility + + − − − − − + + +
Hearing loss Mixed Sensorineural Sensorineural (normal
hearing at 2 years)
Sensorineural − − Sensorineural Sensorineural Mixed (normal
hearing until
3 years)
Conductive
Submucous cleft
palate and bifid
uvula
− − − − − − − − + +
Haematuria + + + + + + − + − −
Nephrocalcinosis − − − − − − − − + +
Flattened nasal
bridge
+ + + + + + + + + +
Midface
hypoplasia
+ + + + + + − + + +
Digital
abnormalities
Persistent fetal
pads, increased
space between
index and middle
fingers as well as
first and second
toes, second toe
clinodactyly
Persistent fetal pads,
increased space
between index and
middle fingers as well
as first and second
toes, second toe
clinodactyly
Persistent fetal pads,
metaphyseal
dysostosis
Persistent fetal pads,
metaphyseal
dysostosis
− − Bilateral
syndactyly of
second and third
toes and
clinodactyly of
second toes
Small hands and fingers,
laxity of finger joints,
flatfeet, bilateral sandal
gaps
Square hands and
fifth finger
clinodactyly
Square
hands and
fifth finger
clinodactyly
Ocular
abnormalities
Myopia Microstrabismus − − Hyperopia and
astigmatism
Hyperopia – – – Cataract,
convergent
squint
Speech and
language delay
Receptive and
expressive speech
delay (measured at
5 years and
9 months,
predicted age 2–3
and 1 years,
respectively)
Developmental delay
(less severe phenotype
compared with
brother (1))
MR (measured at
8 years, patient
functioning at the
level of 5 years)
MR Non-verbal at
age 5Some
sounds
Significant
delay at age 2
Started speech
at age 3 years
and 6 months
MR (measured at
4 years, patient
functioning at level of
2 years)
Early delay, normal
at age 4
No words at
2 years,
normal at
age 5
Delayed reading
and writing
ability
+ + + + + + + + + +
Elliptocytosis + + − − − − − − − −
Cardiac
abnormalities
RBBB, PDA,
non-stenotic
Mild mitral and
tricuspid regurgitation
− − − − − − −
Continued
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scattering of elliptotic cells consistent with the (mild to moder-
ate) ‘elliptocytosis’ originally reported by Jonsson et al.1
Absence of elliptocytosis in other studies with microdeletions
spanning AMMECR1 may be due to laboratory under-reporting,
particularly if the red cell morphology is subtle. Moreover, aber-
rant red cell morphology was absent in the younger half-sibling
from this study, which may instead reﬂect variable penetrance or
demonstrate a delay in phenotype onset; however, elliptocytosis
was detected at 15 months in one of the affected brothers from
the Jonsson et al study, where the entire AMMECR1 gene was
deleted.
The single point mutation in AMMECR1 in this study
accounts for early speech and language delay, hypotonia,
midface hypoplasia and elliptocytosis, and is found in associ-
ation with nephrocalcinosis, cleft palate, biﬁd uvula, hearing
loss, hypercalciuria, strabismus, cataracts, hypermobility, hypo-
tonia and delay in eruption of primary dentition; although the
phenotypic penetrance is varied. The strong interactions
between AMMECR1 and neighbouring proteins of the AMME
locus render genotype/phenotype stratiﬁcation difﬁcult.
Nephrocalcinosis, hypercalciuria, cataracts (in proband II(2)),
submucous cleft palate and biﬁd uvula are unique to our study
and may be entirely incidental; we do not have sufﬁcient evi-
dence in support of any causal relationship between AMMECR1
and these manifestations. It is possible, though unlikely, that the
half-brothers may have a second (unrelated) condition that
explains their additional features. We excluded known genetic
causes for nephrocalcinosis and idiopathic hypercalciuria in 12
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Figure 5 A peripheral blood ﬁlm (two ﬁelds of view and one closer
image) of proband II(1) reported as ‘elliptical cells seen’.
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of 14 genes assessed. Two genes, PTH and CLDN14, had sub-
optimal gene coverage; and although no variants were found,
we are cautious to exclude them. However, we are reassured
that both CLDN14 and PTH are not on the X chromosome.
CONCLUSIONS
In this study, we have applied contemporary sequencing technol-
ogy and unbiased ﬁltering to a half-brother pair and identiﬁed a
single point mutation within an X-linked gene that causes a
severe phenotype, previously described as part of a contiguous
gene deletion syndrome. Functional analysis shows that the
novel mutation in AMMECR1 affects protein localisation, pos-
sibly due to degradation of the mal-folded protein. We propose
that AMMECR1 has a critical role in the extrarenal manifesta-
tions of AMME, either alone or due to its predicted protein–
protein interactions with other genes in the AMME locus. Our
study narrows the AMME locus to a single point mutation in
AMMECR1 that appears critical in the pathogenesis of midface
hypoplasia and elliptocytosis, and contributes to early speech
and language delay, hypotonia and hearing loss, and may, in
addition, play a role in dysmorphism, nephrocalcinosis and sub-
mucous cleft palate.
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